SMN1抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using SMN1 mouse mAb against HepG2 (1), Hela (2), K562 (3), Jurkat (4), SKBR-3 (5), A431 (6) and Cos7 (7) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using SMN1 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human testis tissues (left) and lung cancer tissues (right) using SMN1 mouse mAb with DAB staining.    

  
  

The survival motor neuron 1 (SMN1) gene encodes the SMN protein, essential for the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs) and motor neuron survival. Loss of SMN1 function due to mutations or deletions causes spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. SMN1 antibodies are critical tools for studying SMN protein expression, localization, and function in both research and diagnostic contexts. These antibodies are typically developed against specific epitopes of the SMN protein, enabling detection via techniques like Western blot, immunohistochemistry, or immunofluorescence.

Since SMN1 and its nearly identical paralog SMN2 differ by a single nucleotide (affecting protein splicing efficiency), antibodies must distinguish between full-length SMN (primarily from SMN1) and truncated isoforms (from SMN2) to assess functional protein levels. High-quality SMN1 antibodies aid in understanding SMA pathogenesis, monitoring therapeutic responses (e.g., antisense oligonucleotides or gene therapy), and validating SMN-upregulating drugs. Challenges include ensuring specificity due to the high homology between SMN1 and SMN2-derived proteins. Recent advancements in antibody engineering have improved selectivity, supporting precision in basic research and clinical applications aimed at mitigating SMA progression.